Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-388-8 | CAS number: 13769-43-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin irritation / corrosion
Administrative data
- Endpoint:
- skin irritation: in vitro / ex vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2012-11-07 to 2012-11-12
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method)
- Version / remarks:
- adopted 2010-07-22
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.46 (In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test)
- Version / remarks:
- , 2009
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: In vitro EpiDerm TM Skin irritation Test (EPI-200-SIT) for use with MatTek Corporation's Reconstructed Human Epidermal Model EpiDerm (EPI-200), Rev. 1/19/2010
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- signed 2009-03-30
Test material
- Reference substance name:
- Sodium metavanadate
- IUPAC Name:
- Sodium metavanadate
- Reference substance name:
- Sodium metavanadate
- EC Number:
- 237-272-7
- EC Name:
- Sodium metavanadate
- Cas Number:
- 13718-26-8
- Molecular formula:
- NaVO3
- IUPAC Name:
- 237-272-7
- Reference substance name:
- 13718-26-8
- Cas Number:
- 13718-26-8
- IUPAC Name:
- 13718-26-8
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material: Sodium metavanadate
- Trivial name: Sodium metavanadate
- Molecular formula: NaVO3
- Physical state: white powder
- Storage condition of test material: at room temperature (further detailed: Harlan CCR SOP SUBST.doc)
Constituent 1
Constituent 2
Constituent 3
Test animals
- Details on test animals or test system and environmental conditions:
- Not applicable - Since this is an in vitro study there is no information on test animals.
Test system
- Vehicle:
- other: Dulbecco's Phosphate Buffered Saline (DPBS)
- Amount / concentration applied:
- TEST MATERIAL
- Amount(s) applied (volume or weight with unit): approximately 25 mg (using a weighing spoon) of the test item were applied to each tissue replicate, wetted with the vehicle, and spread to cover the tissue.
VEHICLE
- Amount(s) applied (volume or weight with unit): 25 μL of Dulbecco's Phosphate Buffered Saline - Duration of treatment / exposure:
- 60 minutes
- Observation period:
- not applicable
- Number of animals:
- not applicable
- Details on study design:
- CELL CULTURE
Epi-200 SIT kits (Lot No. 16852) and MTT-100 assays diluent were purchased from MatTek Corporation (82105 Bratislava, Slovakia). The EpiDerm™ tissue consists of normal, human-derived epidermal keratinocytes which have been cultured to form a multilayered, highly differentiated model of the human epidermis. It consists of organized basal, spinous and granular layers, and a multi-layered stratum corneum containing intercellular lamellar lipid layers arranged in patterns analogous to those found in vivo. The EpiDerm™ tissues (surface 0.6 cm²) are cultured on specially prepared cell culture inserts (MILLICELLs®, 10 mm ∅).
EpiDerm™ tissues were shipped at 4 °C on medium-supplemented agarose gels in a 24-well plate and reached the laboratory on November 06, 2012. On day of receipt the preincubation phase of the EpiDerm™ tissues started.
The RhE model supplier ensured and demonstrated that each batch of the RhE model used met defined production release criteria, e.g. viability, barrier function and morphology (please refer to "Attached background material" below).
TEST FOR DIRECT MTT REDUCTION
For a correct interpretation of results it was necessary to assess the ability of the test item to directly reduce MTT. To test for this ability approximately 25 mg of the test item were added to 1 mL of MTT solution (using a weighing spoon) and the mixture was incubated in the dark at room temperature for 60 minutes. Untreated MTT medium was used as control. If the colour of the MTT would turn blue/purple, the test item is assumed to have reduced MTT.
The optical evaluation of the MTT-reducing capacity of the test item after 1-hour incubation with the MTT-reagent indicated that it did not turn blue. Therefore, the test item did not reduce MTT directly and a functional test with freeze-killed tissue was not deemed necessary.
TREATMENT
- Pre-warming of EpiDerm™ Tissues:
One day prior to the performance, the plastic bag containing the 24-well plate with epidermal tissues was opened under sterile conditions. Under a airflow using forceps, the gauze was removed and the inserts were taken out. Any remaining agarose that adheres to the outer sides of the inserts was removed by gentle blotting on the sterile filter paper or gauze, and the tissues were placed in the empty, sterile 6-well plate. Prior to the exposure of the test item and of the controls the EpiDerm™ tissues were inspected for quality: If necessary, it was taken care, that
1. air bubbles between agarose and insert were not > 30% of the total surface,
2. liquid on top of the insert was removed with steriles cotton tips,
3. if again moisture is observed on top of the inserts after the pre-incubation or in case of visible defects, the respective skin models were discarded.
0.9 mL of the DMEM based, serum-free assay medium (20 – 25 °C) was pipetted into each of the wells of the sterile 6-well plates. The inserts with the EpiDerm™ tissues were placed in the upper wells, and were pre-incubated for 60 minutes in the incubator (37 ± 1.5 °C, 5 ± 1% CO2, 95 ± 5% RH). Afterwards, the inserts were transferred from the upper wells into the lower wells of the 6-well plates, and, the preincubation was continued for further 24 hours (37 ± 1.5 °C, 5 ± 1% CO2, 95 ± 5% RH).
- Treatment: after pre-incubation of EpiDerm™ tissues was completed, the negative and positive control and the test item were added into the insert atop the corresponding EpiDerm™ triplicate tissues. The 6-well plates were placed into the incubator for 35 minutes at 37 ± 1.5 °C, 5 ± 0.5 % CO2, 95 ± 5% RH. Thereafter, plates were removed from the incubator and placed into the sterile hood until the exposure period of 60 minutes was completed.
At the end of the treatment interval the inserts were removed immediately from the 6-well plate and tissues were gently rinsed with DPBS for at least 15 times in order to remove any residual test material. After the rinsing, the inserts were submerged in DPBS for at least three times. Afterwards the inserts were again rinsed with DPBS from the inside and the outside. Excess DPBS was removed by gently shaking the inserts and blotting the bottom with sterile blotting paper. The tissues were then transferred into new 6-well plates with 0.9 mL of fresh assay medium in the upper row. The surface of the tissues was carefully dried using sterile cotton tipped swaps. Tissues were incubated for about 23 hours at 37 ± 1.5 °C, 5 ± 0.5 % CO2.
New 6-well plates (or lower row of the same plates) were filled with 0.9 mL of fresh assay medium, and the inserts were transferred onto the new plates. The wells were incubated for nearly 18 hours post-incubation at 37 ± 1.5 °C, 5 ± 0.5 % CO2. The complete incubation period was about 41 hours.
MTT ASSAY
Cell viability is measured by dehydrogenase conversion of MTT [(3-4,5-dimethylthiazole 2-yl) 2,5-diphenyl-tetrazoliumbromide], in cell mitochondria, into a blue formazan salt that is quantitatively measured after extraction from tissues (Faller, C., Bracher, M., Dami, N., Roguet, R., 2002. Predictive ability of reconstructed human epidermis equivalents for assessment of skin irritation of cosmetics. Toxicology in vitro 16 (5), 557-552).
The percent reduction of cell viability in comparison of untreated negative controls is used to predict skin irritation potential (see OECD TG 439) and is used for the purpose of classification as irritating or non-irritating to skin according to chemical regulation (Regulation (EC) No 1272/2008 (EU CLP), UN GHS).
After the 42-hours incubation period was completed for all tissues and exposure groups, culture inserts were transferred from the holding plates to the MTT-plates containing 300 µL MTT solution. After a 3-hour incubation period (37 ± 1 °C, 5 ± 0.5 % CO2), the MTT solution was aspirated from the wells, and the wells were rinsed three times with DPBS. Inserts were transferred onto new 24-well plates. The inserts were immersed into extractant solution by gently pipetting 2 mL extractant solution (isopropanol) in each insert. The level rose above the upper edge of the insert, thus tissues were completely covered from both sides. The 24-well plate was sealed to inhibit the isopropanol evaporation. The formazan salt was extracted for about 69 hours at room temperature.
After the extraction period was completed, the inserts were pierced with an injection needle to allow the extract to run into the well from which the insert was taken. Afterwards the insert was discarded. The 24-well plates were placed on a shaker for 15 minutes until the solution was homogeneous in colour.
Per each tissue, 3 × 200 μL aliquots of the blue formazan solution were transferred into a 96-well flat bottom microtiter plate from the 15 minutes exposure. The optical density (OD) was read in a microplate reader (Versamax® Molecular Devices, 85737 Ismaning, Germany) with a 570 ± 1 nm filter. Mean values were calculated from the 3 wells per tissue.
EVALUATION OF RESULTS
The mean optical density (OD) of the three negative control tissues was calculated. This value corresponds to 100% tissue viability in the current test. For each individual tissue treated with the test item or the positive control the individual relative tissue viability was calculated according to the following formulas:
Relative viability (%) = (OD test item/ OD mean of negative control) X 100
For the test item and the positive control, the mean relative viability ± relative standard deviation of the three individual tissues was calculated and used for classification according to the following prediction model:
if the mean relative tissue viability of three individual tissues is reduced below 50% of the negative control, the test item needs to be classified and labeled for its skin irritation potential: Category 2 – irritant, H315 according to Regulation (EC) No 1272/2008 (Xi, R38 – irritating to skin according to Directive 67/548/EEC).
ACCEPTABILITY OF THE ASSAY
Concurrent negative controls (NC) and positive controls (PC) were used in each run to demonstrate that viability (with the NC), barrier function and resulting tissue sensitivity (with the PC) of the tissues were within a defined historical acceptance range.
Criterion 1 (negative control): the absolute OD (at 570 nm) of the negative control tissues in the MTT test is an indicator of tissue viability obtained after the shipping and storing procedure and under specific conditions of the assay. Tissue viability is meeting the acceptance criterion if the mean OD570 of the negative control tissues is ≥ 1.0 and ≤ 2.5 in accordance with the OECD 439 guideline.
Criterion 2 (positive control): an assay is meeting the acceptance criterion if mean relative tissue viability of the positive control is ≤ 20% (threshold established at the laboratory).
Criterion 3: Standard deviation: the SD of 3 identical tissue replicates should be < 18%.
OD values should not be below historically established boundaries.
According to the OECD 439 guideline, the acceptance limit of the ET50 should be between 4.8 hours and 8.7 hours after treatment with 1% Triton X-100 (QC batch release criteria). The respective tissue passed this functionality test (please refer to "Attached background material" below).
Results and discussion
In vitro
Results
- Irritation / corrosion parameter:
- other: other: relative viability (%)
- Value:
- 72.2
- Remarks on result:
- other:
- Remarks:
- Basis: mean. Time point: after 60 min. incubation. Reversibility: no data. (migrated information)
In vivo
- Irritant / corrosive response data:
- Compared to the relative absorbance value of the negative control, the mean relative absorbance value decreased to 72.2% after exposure of the skin tissues to the test item sodium metavanadate. This value is well above the viability threshold for irritancy of ≤ 50%. Therefore, the test item is not considered to possess a skin irritating potential.
Any other information on results incl. tables
HISTORICAL DATA
Positive Control |
Negative Control |
||
Number of Studies |
67 |
Number of Studies |
67 |
Period |
May 2010 – November 2012 |
Period |
May 2010 – November 2012 |
Mean Viability |
6.6% |
Mean Absorption |
1.717 |
Standard Deviation |
2.1% |
Standard Deviation |
0.274 |
Range of Viabilities |
4% - 9.4% |
Range of Vabilities |
1.423 – 2.651 |
Table 1: Results after treatment with sodium metavanadate and the controls
Dose group |
Treatment interval |
Absorbance
|
Absorbance
|
Absorbance
|
Mean Absor-bance
|
Mean Rel. Absorbance [% of Negative Control]**
|
Negative control |
60 min |
2.117 |
2.423 |
2.175 |
2.239 |
100.0 |
Positive control |
60 min |
0.091 |
0.088 |
0.077 |
0.085 |
3.8*** |
Test item |
60 min |
0.844 |
0.835 |
0.740 |
0.806 |
36.0 |
* Mean of three replicate wells after blank correction
** relative absorbance [rounded values]: 100 x (absorbancetest item)/(absorbance negative control)
*** The viability of the positive control is below the historical limit of 4.0%. Nevertheless, since the positive control induced a clear positive effect, and is only slightly below the historical limit, it can still be considered as valid.
- after treatment with the negative control, the absorbance values were well above the required acceptability criterion of mean OD ≥ 1.0 and ≤ 2.5 for the 60 minutes treatment interval, and thus assuring the quality of the tissues.
- treatment with the positive control induced a decrease in the relative absorbance as compared to the negative control to 3.8%, and thus assuring the validity of the test system.
- the relative standard deviations of readings for tissue replicates of the test item, positive and negative controls were all below 18%, respectively (threshold of the "OECD Guideline for the Testing of Chemicals 439: In vitro Skin Irritation: Reconstructed Human Epidermis Test Method”: 18%), thus assuring the validity of the study.
The optical evaluation of the MTT-reducing capacity of the test item after 1-hour incubation with the MTT-reagent indicated that it did not turn blue and thus did not reduce MTT directly.
Applicant's summary and conclusion
- Interpretation of results:
- not irritating
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- In this study and under the reported experimental conditions of the Human Skin Model Test, the test item sodium metavanadate is not irritant to skin.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.